Clinical TrialID 1423
Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)
NCT00464919
Hepatocellular Carcinoma
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 1423
- Evidence Id
- 1423
- Core Evidence Id
- 1423
- Source Clinical Trial Id
- 1403
- Herb2 Clinical Trial Id
- HBCT001403
- Nct Id
- NCT00464919
- Title
- Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 2
- Study Result
- No
- Study Condition
- Hepatocellular Carcinoma
- Study Type
- Interventional
- Study Design
- Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: Sorafenib|DRUG: tegafur/uracil (UFUR®)
- Intervention Allocation
- Non_Randomized
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 50
- Outcome Measure
- To determine the progression- free survival of sorafenib plus tegafur/uracil (UFUR®) for the treatment of advanced or metastatic HCC., 2007~2008
- Sponsor Collaborator
- National Taiwan University Hospital
- Funded By
- OTHER
- Location
- National Taiwan University Hospital, Taipei, 100, Taiwan
- Other Id
- 950914
- Start Date
- 2007-04
- Primary Completion Date
- Completion Date
- 2009-03
- First Posted
- 2007-04-24
- Results First Posted
- Last Update Posted
- 2009-07-07
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT00464919
- Title Cn
- Title En
- Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)
- Bilingual Status
- semi_complete